Literature DB >> 9096431

Oestradiol and testosterone blood levels in patients with viral cirrhosis and hepatocellular carcinoma.

S Pignata1, B Daniele, M G Galati, G Esposito, P Vallone, F Fiore, P Ricchi, M Pergola.   

Abstract

BACKGROUND: Patients with alcoholic cirrhosis show hypogonadism and feminization associated with sex hormone imbalance due to enhanced aromatization of testosterone and subsequent reduced testosterone and increased oestradiol blood levels. Because oestrogens modulate hepatocyte proliferation and oestrogen receptors are present in liver cirrhosis and hepatocellular carcinoma, it has been proposed that sex hormone imbalance can play a role in liver carcinogenesis. Trials with the oestrogen receptor antagonist tamoxifen have been performed with conflicting results.
OBJECTIVES: To investigate oestradiol and testosterone blood levels in men with viral cirrhosis and hepatocellular carcinoma and also to investigate changes in sex hormone circulating levels induced by tamoxifen treatment. PATIENTS AND METHODS: Oestradiol and testosterone blood levels were evaluated in 32 male patients with postviral cirrhosis and hepatocellular carcinoma at the time of diagnosis and during the follow-up, and in 20 healthy controls. In eight patients, hormone levels were also assayed during treatment with tamoxifen (40 mg/day). No patient had a history of high alcohol intake.
RESULTS: Oestradiol values observed at the time of diagnosis were 56.1 +/- 54.5 pmol/l, while testosterone values were 13.6 +/- 8.0 pmol/l. There was no relationship between oestrogen values and age, while higher oestradiol values were observed in patients with advanced cirrhosis (Child B and C); conversely, testosterone levels progressively and significantly decreased from cirrhosis Child A (15.1 +/- 9.7) to C (7.7 +/- 7.1) (P < 0.05). Tamoxifen treatment (40mg/day) for 1 month in eight patients increased oestradiol values (62.2 +/- 77.0 vs. 156.4 +/- 83 pmol/l, P < 0.05), while testosterone levels decreased (15.1 +/- 6.8 vs. 8.5 +/- 10.6 pmol/l). However, these changes were not associated with clinical signs or symptoms of feminization. Oestrogen levels decreased after 6 months of tamoxifen treatment. No significant change in hormone levels was observed in patients not treated with tamoxifen. Unlike patients with alcoholic cirrhosis, in male patients with viral cirrhosis and hepatocellular carcinoma there were no significant alterations in blood oestradiol and testosterone levels, although a certain degree of sex hormone imbalance was observed in those with advanced cirrhosis. Treatment with tamoxifen (40 mg/day) did not induce clinical manifestations of sex hormone imbalance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9096431     DOI: 10.1097/00042737-199703000-00012

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  12 in total

1.  Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection.

Authors:  Vincent Lo Re; Jessica Volk; Craig W Newcomb; Yu-Xiao Yang; Cristin P Freeman; Sean Hennessy; Jay R Kostman; Pablo Tebas; Mary B Leonard; A Russell Localio
Journal:  Hepatology       Date:  2012-10-14       Impact factor: 17.425

2.  Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.

Authors:  D D Byrne; C W Newcomb; D M Carbonari; M S Nezamzadeh; K B F Leidl; M Herlim; Y X Yang; S Hennessy; J R Kostman; M B Leonard; A R Localio; V Lo Re
Journal:  J Viral Hepat       Date:  2015-03-06       Impact factor: 3.728

3.  Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?

Authors:  A Gaudio; A Lasco; N Morabito; M Atteritano; C Vergara; A Catalano; W Fries; A Trifiletti; N Frisina
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

4.  MELD score, insulin-like growth factor 1 and cytokines on bone density in end-stage liver disease.

Authors:  Rebecca Mitchell; Jill McDermid; Mang M Ma; Constance L Chik
Journal:  World J Hepatol       Date:  2011-06-27

5.  Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection.

Authors:  Dana D Byrne; Craig W Newcomb; Dena M Carbonari; Melissa S Nezamzadeh; Kimberly B F Leidl; Maximilian Herlim; Yu-Xiao Yang; Sean Hennessy; Jay R Kostman; Mary B Leonard; A Russell Localio; Vincent Lo Re
Journal:  J Hepatol       Date:  2014-04-05       Impact factor: 25.083

6.  Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.

Authors:  Vincent Lo Re; Giovanni Guaraldi; Mary B Leonard; Anthony R Localio; Jennifer Lin; Gabriella Orlando; Lucia Zirilli; Vincenzo Rochira; Jay R Kostman; Pablo Tebas
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

Review 7.  Cholestasis and metabolic bone disease - a clinical review.

Authors:  Rudolf W Gasser
Journal:  Wien Med Wochenschr       Date:  2008

8.  Bone mineral density and its determinants in men with opioid dependence.

Authors:  Frank Gotthardt; Christine Huber; Clara Thierfelder; Leticia Grize; Marius Kraenzlin; Claude Scheidegger; Christian Meier
Journal:  J Bone Miner Metab       Date:  2016-01-08       Impact factor: 2.626

Review 9.  Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis.

Authors:  Huan V Dong; Yamnia I Cortés; Stephanie Shiau; Michael T Yin
Journal:  AIDS       Date:  2014-09-10       Impact factor: 4.177

10.  Association Between Chronic Hepatitis B Virus Infection and Risk of Osteoporosis: A Nationwide Population-Based Study.

Authors:  Chien-Hua Chen; Cheng-Li Lin; Chia-Hung Kao
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.